Interim report January - March 2019
Mölndal, May 15, 2019 – Vicore Pharma Holding (publ) publishes the interim report for the first quarter 2018.Important events during the first quarter · In January, the directed share issue of approximately 160 MSEK was approved by an Extraordinary General Meeting. The total number of shares after the share issue amounts to 42,374,714. Important events after the period · Vicore Pharma announced on April 23 that it has selected the disease diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21). It complements the primary indication, idiopathic